Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 747 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer May 8, 2020 Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in... June 8, 2026 Medicare Advantage Plans: Read the Fine Print November 16, 2020 FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell... October 8, 2024 Load more HOT NEWS 2021/22 in review: Charity looks to the future with ambitious new... More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer Can Getting a Tattoo Cause Cancer? Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer
